Drug Profile
Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics
Alternative Names: STP 503Latest Information Update: 04 Nov 2020
Price :
$50
*
At a glance
- Originator General Research Laboratory; Sirnaomics
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Breast-cancer in France (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
- 08 Sep 2016 Preclinical trials in Breast cancer in France (Parenteral)